Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL645741 | 0.91 | CHRM3 (0.67) | CHRM3 | |
| SCHEMBL356694 | 0.90 | CHRM3 (0.63) | CHRM3 | |
| SCHEMBL644274 | 0.90 | CHRM3 (0.61) | CHRM3 | |
| SCHEMBL266142 | 0.89 | CHRM3 (0.67) | CHRM3 | |
| SCHEMBL356481 | 0.89 | CHRM2 (0.74) | CHRM3 | |
| SCHEMBL644464 | 0.88 | CHRM3 (0.61) | CHRM3 | |
| SCHEMBL645124 | 0.88 | CHRM3 (0.60) | CHRM3 | |
| SCHEMBL645322 | 0.88 | CHRM3 (0.60) | CHRM3 | |
| SCHEMBL644566 | 0.88 | CHRM3 (0.60) | CHRM3 | |
| SCHEMBL713681 | 0.88 | CHRM3 (0.62) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136550-A1 | PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME | THERAVANCE BIOPHARMA R&D IP, LLC | 2025-05-01 | — | — | US | disclosed |
| EP-2593429-B1 | PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-06-03 | — | — | EP | disclosed |
| US-9035061-B2 | Process for preparing a biphenyl-2-ylcarbamic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-05-19 | — | — | US | disclosed |
| US-8754225-B2 | Process for preparing a biphenyl-2-ylcarbamic acid | THERAVANCE, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140121378-A1 | PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID | THERAVANCE, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2593429-A1 | PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID | Theravance, Inc. (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20120016130-A1 | PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC | 2012-01-19 | — | — | US | disclosed |
| WO-2012009166-A1 | PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID | THERAVANCE, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136550-A1 | PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME | CYP4B1, KDM4B, CYP3A4 | CHRM3 1755/4885 |
| US-20140121378-A1 | PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID | CYP4B1, KDM2B, CYP26B1 | CHRM3 2296/4885 |
| US-20120016130-A1 | PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID | CYP4B1, KDM2B, CYP26B1 | CHRM3 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.